Pelthos Therapeutics Inc. reported second quarter 2026 financial results, announcing net product revenue of $15.4 million for its lead drug Zelsuvmi, a 45% increase from the first quarter's $10.7 million. The company dispensed 11,925 units to 4,571 unique prescribers during the quarter. Pelthos reported a net loss of $23.4 million and an adjusted EBITDA loss of $5.7 million. Cash reserves stood at $24.2 million as of June 30, 2026. The filing also references a prior restatement of first quarter 2026 financial statements. Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on developing and marketing treatments for cutaneous infectious diseases.

Pelthos Therapeutics Inc. announced on August 12, 2026, that it will restate its condensed consolidated financial statements for the quarter ended March 31, 2026, due to a misapplication of ASC 820 regarding Level 3 fair value measurements of convertible debt. The restatement increases total liabilities by $15.8 million and accumulated deficit by $14.8 million, while reducing stockholders' equity by $1.0 million through other comprehensive income. The company identified a material weakness in internal control over financial reporting related to the valuation of these instruments, specifically concerning provisions in a January 2026 subordination agreement. This error resulted from ineffective controls that failed to properly evaluate extended payoff terms and conversion rate reset features. The restatement will be filed as Amendment No. 1 to the Form 10-Q for the affected period and has no impact on liquidity or operating results. Pelthos Therapeutics Inc. operates in the biotechnology industry, focusing on drug discovery and development.